Fiocruz Bio-Manguinhos

Fiocruz Bio-Manguinhos
Name	Bio-Manguinhos
Native name	Bio-Manguinhos
Established	1976
Founder	Oswaldo Cruz Foundation
Type	Public research institute
Location	Rio de Janeiro, Brazil

Fiocruz Bio-Manguinhos is a Brazilian public biotechnology institute specializing in vaccine, reagent and biopharmaceutical development and production. It operates within the Oswaldo Cruz Foundation network and maintains activities spanning translational research, industrial manufacturing, and global health collaborations. The institute engages with national and international partners to support immunization programs, epidemic response, and capacity building.

History

Bio-Manguinhos traces roots to the industrialization of biologicals in Brazil during the 20th century, evolving from early vaccine initiatives associated with Instituto Oswaldo Cruz and legacy activities of Instituto Vacina and municipal laboratories in Manguinhos, Rio de Janeiro. During the 1970s and 1980s expansion of public health infrastructure, links formed with Ministry of Health (Brazil), Fundação Nacional de Saúde, and programs such as the Programa Nacional de Imunizações and bilateral cooperation with Pan American Health Organization and World Health Organization. Institutional milestones involved technology transfer agreements with international producers like Institut Pasteur, GlaxoSmithKline, Sanofi, and partnerships under frameworks exemplified by the PAHO Revolving Fund and projects funded by Inter-American Development Bank. Over decades Bio-Manguinhos participated in responses to outbreaks ranging from dengue fever and yellow fever to the COVID-19 pandemic, collaborating with research centers such as Fiocruz Ceará, Fiocruz Pernambuco, Fiocruz Bahia, Fiocruz Brasília and academic groups at Federal University of Rio de Janeiro, University of São Paulo, Universidade Federal de Minas Gerais and international laboratories including National Institutes of Health and Karolinska Institutet.

Organization and Governance

The institute functions as an industrial unit within the Oswaldo Cruz Foundation system, subject to governance by Brazil’s Ministry of Health (Brazil) and oversight mechanisms from agencies like ANVISA and Foundation for the Support of Research of the State of Rio de Janeiro. Its organizational structure integrates departments for research, production, quality assurance, regulatory affairs, and international cooperation, coordinating with entities such as Brazilian Development Bank (BNDES), Brazilian Ministry of Science, Technology and Innovation, and regional health secretariats in State of Rio de Janeiro. Management operates through boards, technical committees and accords with labor unions such as FENASPS and professional associations including Brazilian Society for Virology and Brazilian Biochemical Society. Strategic planning interacts with multilateral stakeholders like Gavi, the Vaccine Alliance, Coalition for Epidemic Preparedness Innovations, and bilateral bodies exemplified by Ministério da Saúde accords and memoranda with United States Agency for International Development.

Research and Development

R&D programs combine basic virology, immunology, process development and applied biotechnology. Research lines span work on viral pathogens like influenza virus, Zika virus, SARS-CoV-2 and measles virus and bacterial agents such as Mycobacterium tuberculosis and Neisseria meningitidis; projects integrate methodologies from groups affiliated with Oswaldo Cruz Institute, Butantan Institute, Evandro Chagas Institute and university partners including Universidade de São Paulo, Universidade Federal do Rio Grande do Sul and Federal University of Minas Gerais. Bio-Manguinhos runs preclinical research in collaboration with contract research organizations, CROs, and networks such as RedeVírus MCTI and clinical trial sites coordinated with Brazilian Clinical Trials Network and Oswaldo Cruz Foundation clinical research platforms. Technology transfer and scale-up activities have involved collaborations with Institut Pasteur de Dakar, Imperial College London, University of Oxford and companies like Bio-Mérieux and Merck & Co. to support vaccine adjuvantation, antigen expression, and formulation. Intellectual property management liaises with entities such as National Institute of Industrial Property (Brazil) and international patent offices.

Manufacturing and Products

The institute’s manufacturing portfolio includes live-attenuated, inactivated and recombinant vaccines, diagnostic reagents and biologicals produced in facilities compliant with Good Manufacturing Practice standards inspected by ANVISA and meeting World Health Organization prequalification processes. Product lines historically and currently encompass vaccines for yellow fever, hepatitis B, tetanus, diphtheria, pertussis, influenza, and reagents for serology and molecular diagnostics used by healthcare networks like Sistema Único de Saúde and reference laboratories including Instituto Evandro Chagas. Manufacturing infrastructure parallels industrial partners such as Bio-Manguinhos production sites (industrial campuses), with engineering collaborations from firms like Siemens Healthineers and GE Healthcare Life Sciences for bioreactors, chromatography systems and cold-chain technologies coordinated with logistics providers including Brazilian Air Force transport for emergency shipments and WHO emergency stockpile mechanisms.

Public Health Initiatives and Partnerships

Bio-Manguinhos engages extensively with public health programs, supplying immunization campaigns coordinated by Ministry of Health (Brazil), vaccination strategies under the Programa Nacional de Imunizações, and outbreak response operations involving National Health Surveillance Agency (ANVISA), PAHO and WHO. Partnerships extend to global health initiatives with Gavi, the Vaccine Alliance, UNICEF, World Health Organization, PAHO Revolving Fund and bilateral cooperation with agencies such as United States Agency for International Development, European Commission health programs and Latin American networks including Mercosur Health and Instituto Butantan. Capacity strengthening and training programs are conducted with universities like Federal University of Rio de Janeiro and international collaborators including London School of Hygiene & Tropical Medicine and Johns Hopkins Bloomberg School of Public Health.

Regulation, Quality Control, and Biosafety

Quality control systems comply with standards enforced by ANVISA, align with WHO prequalification guidelines and interact with national regulators such as Ministry of Health (Brazil) and inspection regimes used by agencies like European Medicines Agency when engaged in exports. Biosafety and biosecurity practices follow norms from Brazilian regulatory frameworks and international guidance from World Health Organization and Centers for Disease Control and Prevention; institutional biosafety committees coordinate with reference centers such as Evandro Chagas Institute and laboratory networks like RENAVE for pathogen surveillance. External audits, certification processes and pharmacovigilance activities link to pharmacovigilance networks including VigiBase and regional monitoring structures within PAHO.

Category:Biotechnology companies of Brazil Category:Research institutes in Brazil Category:Vaccination